Ipamorelin
Mechanism
This one is selective, and that word is doing real work. It hits the ghrelin receptor, GHS-R1a specifically, and gets growth hormone released without dragging cortisol or prolactin along for the ride.
Key Benefit
Clean GH release profile. Improved sleep, lean mass, and recovery. Often stacked with CJC-1295 for synergistic GH pulse amplification.
Evidence Base
Phase II human trials show the GH release scales with dose, and the safety profile held up. There is no phase III, not yet.
Route & Rationale
Subcutaneous injection (2–3× daily). Short half-life (~2 hours) requires multiple daily doses for sustained GH pulsatility. SC injection standard.
Interactions
Monitor IGF-1. Synergistic with CJC-1295. May transiently increase hunger.
Regulatory Status
Not FDA-approved. Filed under GH secretagogue. WADA has it on the list, same as the rest of this family.
Hard Contraindications
Cancer (active/history), Pregnancy/planning
For information and research purposes only. This is not medical advice and not a recommendation to use this substance. Discuss anything here with your healthcare provider.
